Join Growin Stock Community!

Oncolytics biotech inc.ONCY.US Overview

US StockHealthcare
(No presentation for ONCY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ONCY AI Insights

ONCY Overall Performance

ONCY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ONCY Recent Performance

-6.64%

Oncolytics biotech inc.

0.05%

Avg of Sector

-0.31%

S&P500

ONCY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ONCY Key Information

ONCY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ONCY Profile

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Price of ONCY

ONCY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ONCY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1371.86
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1371.86
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ONCY's latest earnings report released?

    The most recent financial report for Oncolytics biotech inc. (ONCY) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ONCY's short-term business performance and financial health. For the latest updates on ONCY's earnings releases, visit this page regularly.

  • How much debt does ONCY have?

    As of the end of the reporting period, Oncolytics biotech inc. (ONCY) had total debt of 835K, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ONCY have?

    At the end of the period, Oncolytics biotech inc. (ONCY) held Total Cash and Cash Equivalents of 12.35M, accounting for 0.82 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ONCY's EPS continuing to grow?

    According to the past four quarterly reports, Oncolytics biotech inc. (ONCY)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ONCY?

    Oncolytics biotech inc. (ONCY)'s Free Cash Flow (FCF) for the period is -6.66M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ONCY?

    The latest valuation data shows Oncolytics biotech inc. (ONCY) has a Price-To-Earnings (PE) ratio of -4.67 and a Price/Earnings-To-Growth (PEG) ratio of -0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.